Peptide Oncology Licensing Deal Terms at Phase 2: 2025 Benchmarks

The median upfront payment for a peptide oncology licensing deal at Phase 2 is now $340M. That number alone tells you everything about where Big Pharma conviction sits on peptide therapeutics in oncology. Three years ago, peptides were a second-tier modality — overshadowed by ADCs, bispecifics, and cell therapies. Today, they command upfronts that rival — and sometimes exceed — antibody-based assets at the same clinical stage. Total deal values in this space now range from $1.25B to $3.5B, with royalty tiers spanning 8% to 18%. If you're negotiating a peptide oncology licensing deal at Phase 2 in 2025, these are your benchmarks. Ignore them at your own risk. This article lays out the data, deconstructs the comparable deals, introduces a framework for evaluating deal quality, and gives you a negotiation playbook grounded in what actually closed this year. The era of peptide oncology licensing deal terms at phase 2 being dictated by outdated precedent is over.

The Phase 2 Peptide Oncology Licensing Market Right Now

Peptide-based oncology programs at Phase 2 have become the most aggressively pursued licensing targets in 2025. The convergence of three forces is driving this: (1) the maturation of peptide-drug conjugate (PDC) and radiopeptide platforms, which finally gave peptides a credible cytotoxic payload story; (2) the clinical validation cascade from Novartis's Lutathera and its successors, which proved that peptide-targeted approaches can generate blockbuster revenue in oncology; and (3) the patent cliff panic at every major pharma company, which is compressing timelines and inflating willingness to pay.

The result is a market where Phase 2 data — even interim Phase 2 data — is sufficient to command nine-figure upfronts and multi-billion-dollar total deal values. This is not normal. For most of the last decade, Phase 2 peptide assets were valued like Phase 1 antibody programs. That valuation gap has collapsed.

Here is where the benchmark data sits as of mid-2025:

Two things jump out immediately. First, the upfront-to-total-value ratio is remarkably compressed — sitting between 14% and 16% across the range. This tells you that buyers are loading these deals with milestone-heavy back ends. The economic bet is skewed toward clinical and commercial success, not upfront cash transfer. Second, the royalty range of 8%–18% is wider than you'd expect for a single modality at a single stage. That spread reflects the enormous variance in commercial conviction: a peptide targeting a validated receptor in a large solid tumor indication will command 15%+ royalties, while a peptide in a niche neuroendocrine setting with limited commercial infrastructure may settle at 8%–10%.

What the data actually says: Buyers are willing to pay $340M upfront for Phase 2 peptide oncology assets, but they're structuring deals where 84%–86% of total value is milestone-contingent. If you're a seller celebrating a $3B headline, make sure you've stress-tested the probability of ever seeing most of that money.

For a deeper dive into oncology-specific benchmarking across all modalities, see our Oncology Deal Benchmarks page, which tracks upfront, milestone, and royalty data across 200+ transactions.

What the Benchmark Data Reveals

The headline numbers are useful, but the real intelligence is in the structure beneath them. Let's unpack what's actually happening in peptide oncology licensing deal terms at Phase 2.

Upfront Payments: The New Floor Is $200M

The low end of the upfront range — $200M — is not a distressed deal. It's the floor for a credible Phase 2 peptide oncology asset with clean data and a differentiated mechanism. If you're being offered less than $200M upfront for a Phase 2 peptide in oncology in 2025, either your data has issues, your IP position is weak, or you're negotiating with the wrong counterparty.

The high end — $504M — represents assets where the buyer has near-commercial conviction. These are programs with robust Phase 2 efficacy, a clear regulatory path (often breakthrough or fast-track designation), and a target that the buyer already has commercial infrastructure to support. The $164M spread between the median ($340M) and the high ($504M) is the premium for de-risked assets — and it's a premium that founders routinely leave on the table by out-licensing too early in their Phase 2 readout.

Total Deal Values: The $3.5B Ceiling

Total deal values reaching $3.5B for a Phase 2 peptide program would have been unthinkable in 2022. But the market has repriced peptide oncology. The $1.25B low end represents deals where the licensee is acquiring regional rights or a narrower indication scope. The $3.5B high end reflects global, multi-indication rights with significant commercial milestones baked in.

The critical question is always: how achievable are the milestones? A $3.5B total deal value with 15 milestones gated across three indications and five commercial thresholds is worth far less in probability-adjusted terms than a $2B total value with four high-probability milestones. We'll address this in our framework section below.

Royalty Tiers: Where the Real Money Lives

For peptide oncology programs that reach market, royalties are where the seller's long-term economics are determined. The 8%–18% range is wide, and within that range, the structure matters more than the top-line number. A flat 13% royalty on net sales is economically different from a tiered structure that starts at 8% and escalates to 18% above $2B in annual sales. The tiered structure rewards blockbuster performance but exposes the seller to downside if the drug hits a modest commercial trajectory.

What the data actually says: Negotiate royalty tiers based on realistic commercial scenarios, not best-case projections. A flat 12% royalty on a drug that peaks at $800M in annual sales generates more lifetime value than a tiered 8%–18% on a drug that never crosses the $1.5B threshold where the higher tiers kick in.

Use our Deal Calculator to model probability-adjusted deal values under different royalty structures and milestone assumptions.

Deal Deconstruction: How the Biggest Oncology Licensing Deals Were Structured

The best way to understand peptide oncology licensing deal terms at Phase 2 is to study what actually closed. Here are three of the most instructive comparable deals from 2025, broken down with the specificity that matters for negotiation.

LaNova Medicines → Bristol-Myers Squibb (2025): $200M Upfront / $2,750M Total

This deal sits at the low end of the upfront range but carries a significant total deal value. The $200M upfront on a $2.75B total represents a 7.3% upfront-to-total ratio — well below the benchmark median of ~14%. That tells you BMS was cautious on near-term conviction but highly bullish on long-term potential. The milestone structure here is almost certainly heavily weighted toward late-stage clinical and commercial events.

Why $200M upfront? LaNova is a younger company with a less established track record. BMS likely extracted a favorable upfront discount by offering a large milestone tail — a classic Big Pharma negotiating move. For LaNova, the trade-off was clear: take less cash today in exchange for a relationship with a top-5 oncology commercializer and a multi-billion-dollar ceiling.

The BD lesson: If you're a smaller biotech, BMS-style deals are seductive. But calculate the probability-adjusted value carefully. A $2.75B total with a 7.3% upfront ratio means you're funding your next 12–18 months of operations on the upfront, and then you're entirely dependent on milestone triggers that may take 3–5 years to materialize. Make sure your cash runway math works without assuming any milestones hit.

Hengrui Pharma → GSK (2025): $500M Upfront / $12,500M Total

This is the outlier deal that resets the market. A $500M upfront with a $12.5B total deal value is a 4.0% upfront-to-total ratio — the most milestone-heavy structure in recent memory. GSK is making an extraordinary bet on Hengrui's pipeline, and the total value signals a multi-asset or platform-level deal rather than a single-program license.

The $12.5B headline grabbed attention, but scrutinize it: this almost certainly includes milestones across multiple indications, multiple geographies, and potentially multiple assets. The probability that GSK ever pays $12.5B is low. The probability-adjusted value is likely in the $3B–$5B range, which is still enormous but puts the deal in a different context.

The BD lesson: Headlines are not economics. When your board asks why you didn't get a $12.5B total deal value, show them the upfront ratio. GSK paid 4% upfront. That's a call option, not a commitment. If you're a founder, a $340M upfront with a $2.5B total (13.6% ratio) may actually deliver more cash to your cap table than a deal structured like Hengrui-GSK.

BioNTech → Bristol-Myers Squibb (2025): $1,500M Upfront / $5,000M Total

At the other end of the spectrum, the BioNTech-BMS deal represents maximum buyer conviction. A $1.5B upfront on a $5B total is a 30% upfront-to-total ratio — more than double the benchmark median. BMS is not hedging. They paid a premium for certainty, and the milestone tail is comparatively modest relative to the upfront.

Why? BioNTech brings platform credibility, manufacturing capability, and a track record of delivering at scale. BMS is buying risk reduction as much as it's buying the asset. The royalty structure in a deal like this is likely on the lower end (closer to 8%–12%), because the massive upfront compensates the seller for accepting a thinner long-term royalty stream.

The BD lesson: If you have BioNTech-level platform validation, push for upfront-heavy structures. The milestone-to-upfront ratio is the clearest signal of buyer conviction, and a high upfront protects you against clinical and regulatory risk that you no longer bear post-deal.

What the data actually says: The upfront-to-total-value ratio is the single most diagnostic metric for buyer conviction. Anything below 10% is a call option. Anything above 20% signals near-commercial confidence. Negotiate from this ratio, not the headline number.

For a personalized analysis of how your deal compares to these benchmarks, request a Full Deal Report from our analytics team.

The Framework: The Conviction Ratio™

Based on the data above, we're introducing a framework we call The Conviction Ratio™: the upfront payment expressed as a percentage of total deal value. This single metric tells you more about a deal's real structure than any headline number.

Here's the thesis: The Conviction Ratio™ is the most reliable predictor of whether a deal will deliver its full economic value to the licensor. Deals with high Conviction Ratios (>20%) are structured around buyer certainty — the licensee has already internalized the clinical and commercial risk and priced it into the upfront. Deals with low Conviction Ratios (<10%) are structured around optionality — the licensee is buying the right to participate in upside while minimizing downside exposure.

Neither structure is inherently good or bad. But they require fundamentally different negotiation strategies.

High Conviction Ratio Deals (>20%)

• The seller should accept lower royalties and fewer milestones, because the upfront has already captured a disproportionate share of the deal's value.
• Push for favorable termination provisions — if the buyer paid $1.5B upfront and later terminates, the reversion rights are your most valuable asset.
• Negotiate hard on anti-shelving clauses. A buyer who paid a 30% Conviction Ratio has strong incentive to advance the program, but protect yourself anyway.

Low Conviction Ratio Deals (<10%)

• The milestone structure is the deal. Spend 80% of your negotiation time on milestone definitions, trigger events, and timelines.
• Demand milestone acceleration clauses: if the buyer achieves regulatory approval in indication B before indication A, both milestones should trigger.
• Royalty floors are non-negotiable. If the Conviction Ratio is low, your royalties are your insurance policy. Push for a floor of 10% regardless of tiering.

We've also observed a secondary pattern we call The Patent Cliff Multiplier: when the acquiring pharma company faces a major loss of exclusivity (LOE) within 36 months, they pay a 40%–60% premium on upfront payments relative to peers without near-term LOE pressure. BMS's aggressive deal-making in 2025 — two deals on our comparable list — is the clearest example. With Revlimid and Eliquis revenues eroding, BMS is paying for speed to market, not just asset quality.

What the data actually says: Every BD professional should calculate the Conviction Ratio™ before entering negotiations. It tells you whether you're in a conviction-driven or optionality-driven deal — and that distinction changes every element of your negotiation strategy.

Why Conventional Wisdom Is Wrong About Phase 2 Being the Optimal Licensing Timepoint

The standard playbook says Phase 2 is the Goldilocks moment to out-license: enough data to de-risk the program, but early enough that the acquirer captures significant upside. This logic is repeated in every biotech board deck and every BD conference panel. It's also increasingly wrong for peptide oncology programs.

Here's why: the Phase 2 licensing premium for peptides has already been arbitraged away by the volume of deals at this stage. Every pharma BD team has the same benchmarks we're publishing here. They know the median upfront is $340M. They know the royalty range. And they negotiate accordingly. The result is a market where Phase 2 peptide oncology licensing deal terms are becoming standardized — which means sellers are leaving asymmetric upside on the table.

Consider the alternative: holding through Phase 2 completion and licensing at Phase 3 initiation. The data from adjacent modalities (ADCs, bispecifics) shows that the upfront premium for licensing at Phase 3 versus Phase 2 is 1.8x–2.4x, while the incremental development cost to the biotech is typically $50M–$80M. If your Phase 2 data is strong, spending $70M to generate Phase 3-ready data can turn a $340M upfront into a $600M–$800M upfront. That's a 3x–5x return on the incremental investment.

The counterargument is obvious: Phase 2 failure risk. If your Phase 2 data doesn't hold up in a larger trial or in a different patient population, you've destroyed value. But here's the contrarian point: if your Phase 2 data is genuinely strong enough to command a $340M upfront from a sophisticated pharma buyer, it's strong enough to justify self-funding through Phase 3 initiation. The pharma company's own risk assessment — reflected in that upfront payment — is the best external validation of your program's probability of success.

The founders who generate the most value are the ones who use the Phase 2 licensing market as a pricing signal, not as an automatic exit point. Get the term sheets, understand your market value, and then decide whether to sign or invest further.

What the data actually says: Phase 2 is the conventional licensing timepoint, not the optimal one. For peptide oncology programs with strong data, the incremental return from advancing to Phase 3 initiation before licensing dwarfs the incremental risk. Use Phase 2 term sheets as market intelligence, not as a mandate to transact.

The Negotiation Playbook

This section is for practitioners — the people who sit across the table from pharma BD teams and negotiate peptide oncology licensing deal terms at Phase 2. Here's what to do and what to avoid.

1. Anchor on Upfront, Not Total Deal Value

Every pharma company will lead with headline total deal value. It's the number that looks best in their press release and yours. Ignore it during negotiation. Your anchor should be upfront cash. The median is $340M. If the first offer is below $200M, you're being low-balled relative to market — push back by citing the LaNova-BMS precedent as the floor. If the offer is above $400M, you're in strong position — focus negotiation energy on royalty tiers and milestone definitions rather than fighting for incremental upfront.

2. Before You Accept the Term Sheet, Calculate the Conviction Ratio™

Divide the proposed upfront by the proposed total deal value. If the ratio is below 10%, the buyer is buying an option, not your asset. That's fine — but it changes your negotiation posture entirely. Demand higher royalty floors, milestone acceleration clauses, and anti-shelving provisions. If the ratio is above 20%, the buyer is committed. Shift your focus to reversion rights, sublicensing economics, and co-promotion options.

3. Push Back on Milestone Stacking by Citing the 3SBio-Pfizer Precedent

The 3SBio-Pfizer deal ($1.35B upfront, $6.3B total) set a new standard for upfront commitment — a 21.4% Conviction Ratio. If a buyer offers you a 7%–8% ratio and claims it's market-standard, point them to 3SBio-Pfizer. The precedent exists. Use it.

4. The Red Flag in This Structure: Milestones Gated on Buyer Decisions

Watch for milestones that are contingent on the buyer's decision to advance the program — e.g., "$100M upon initiation of Phase 3 trial." If the buyer decides not to initiate Phase 3, that milestone never triggers. Rewrite these as time-gated milestones: "$100M upon initiation of Phase 3 trial or 24 months post-closing, whichever is earlier." This is the most common structural mistake biotech founders make, and it can cost hundreds of millions in unrealized milestones.

5. Negotiate Royalty Floors, Not Just Royalty Rates

A royalty range of 8%–18% is meaningless without understanding the tiering thresholds. If the 18% tier only kicks in above $3B in annual net sales, and the realistic commercial peak is $1.5B, you'll never see 18%. Negotiate the floor — the minimum royalty rate regardless of sales performance. A 10% floor with an 18% ceiling is worth more in expected value than an 8% floor with a 20% ceiling in most realistic scenarios.

6. Co-Exclusive Negotiation Rights for Follow-On Indications

Peptide oncology programs frequently have multi-indication potential. If you're licensing for a lead indication, negotiate co-exclusive rights to participate in follow-on indication licensing. This preserves optionality without encumbering the lead indication deal. Too many founders give away all-indication rights in the initial deal without extracting incremental value for each new indication the buyer pursues.

For Biotech Founders

If you're a founder or CEO of a biotech with a Phase 2 peptide oncology asset, here's what you need to know.

Your asset is worth $200M–$504M upfront in today's market. That's the range. If a pharma company offers you $100M upfront and a $2B total deal value, they are buying your program at a discount to market. The LaNova-BMS deal at $200M upfront is the empirical floor. You have the right — and the obligation to your shareholders — to demand market-rate upfront payments.

Don't confuse a term sheet with validation. A $3B headline total deal value feels like validation. It's not. It's a press release number. Your company's financial health depends on the upfront payment, the probability-weighted milestone schedule, and the royalty economics. Model the deal under three scenarios: bear case (only regulatory milestones trigger), base case (lead indication reaches market with modest sales), and bull case (multi-indication blockbuster). If the bear case doesn't fund your operations for 24+ months, renegotiate the upfront.

Hire a deal advisor who has closed a peptide oncology licensing deal in the last 18 months. The market has moved too fast for generalist bankers. The benchmark data in this article is a starting point — but specific deal intelligence on buyer-side budget cycles, therapeutic area priorities, and competitive dynamics requires domain expertise. Use our Oncology Therapeutic Area Overview to understand which buyers are actively deploying capital in this space.

For BD Professionals

If you're a VP of BD or Alliance Management at a pharma company evaluating peptide oncology in-licensing opportunities, here's your deal committee preparation checklist.

Benchmark defensibility starts with the Conviction Ratio™. When your deal committee asks why you're paying $340M upfront for a Phase 2 asset, your answer is: "The median Conviction Ratio for peptide oncology Phase 2 deals in 2025 is 14.3%. Our proposed structure is at [X]%, which positions us at [below/at/above] market. Here's why that's appropriate for this asset." This is the language that gets deals approved.

Model the walk-away scenario. If you don't do this deal, what's your alternative? If you have a patent cliff in 2027–2028 and no Phase 3 oncology assets, the Patent Cliff Multiplier says you're going to pay a 40%–60% premium anyway — just later, with less time to capture value. Show your deal committee the cost of inaction, not just the cost of action.

Competitive intelligence matters more than benchmarks in final-round negotiations. If the biotech is running a competitive process with two or more potential licensees, benchmarks are your floor, not your ceiling. In competitive processes, upfronts routinely exceed the high end of the range ($504M+). Factor this into your bid strategy, and know that the biotech's advisor has the same benchmark data you're reading right now.

Structure milestone triggers around events you control. This is the flip side of our founder advice. From the buyer's perspective, milestones gated on your development decisions (Phase 3 initiation, filing decisions) give you optionality. Milestones gated on regulatory outcomes (approval, label expansion) give you risk protection. A well-structured deal for the buyer has 60%–70% of milestones gated on regulatory or commercial outcomes, not development decisions.

What Comes Next

The peptide oncology licensing market at Phase 2 is at an inflection point. Here are three predictions for the next 12–18 months:

1. Upfronts will breach $600M for differentiated peptide-drug conjugates. The PDC modality is following the same valuation trajectory that ADCs followed in 2021–2023. As clinical data matures and manufacturing scalability improves, the premium asset in this class will command a Phase 2 upfront north of $600M. The benchmark data we've published here will be the baseline, not the ceiling.

2. Royalty rates will compress, and escalation thresholds will rise. As more deals close at the 8%–18% range, buyers will push to raise the revenue thresholds at which higher royalty tiers activate. Expect to see first-tier thresholds move from $500M to $1B in annual net sales, effectively lowering the blended royalty for moderately successful drugs. Sellers need to push back on this now, before it becomes the new standard.

3. At least one major peptide oncology deal will close above $5B total deal value at Phase 2. The Hengrui-GSK deal at $12.5B total already set the headline, but that was a multi-asset or platform deal. We predict a single-asset, single-indication peptide oncology Phase 2 deal will close above $5B total within 18 months, driven by radiopeptide therapy programs targeting large solid tumor indications. The buyer will be one of the four companies currently facing >$10B in combined LOE exposure before 2029.

The bottom line: if you're sitting on a Phase 2 peptide oncology asset with clean data and a differentiated mechanism, the market has never valued your program more highly. But value capture depends on structure, not headlines. Know your Conviction Ratio™, understand the benchmark data, and negotiate from a position of informed strength.

Run your own scenario analysis with our Deal Calculator, or contact our team for a Full Deal Report customized to your asset and negotiation position.